Panelists discuss how implementing interchangeable biosimilars requires effective communication with providers and patients, emphasizing that educating stakeholders before making changes is essential for successful adoption despite the legal permissions afforded by interchangeability designation.
Interchangeability and Implementation Strategies
Key Themes:
Key Points for Physicians:
Notable Insights:
Taking time up front for stakeholder education prevents complications later and reduces patient anxiety, making it a best practice even when not required.
Clinical Significance: Interchangeability designation provides important operational benefits, but successful biosimilar implementation still requires thoughtful communication, education, and inventory strategies to optimize patient care and system efficiency.
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More